When Your Bowel Suddenly Closes
Imagine your colon — the large intestine — becoming completely blocked. Food and waste have nowhere to go. Pain builds fast. This is called an acute malignant colorectal obstruction (a sudden, cancer-caused bowel blockage), and it is a medical emergency.
For people with left-sided colon or rectal cancer, this happens more often than many realize. Without a quick fix, permanent damage and infection become serious risks.
Two Very Different Fixes
For years, doctors have faced a difficult choice. One option is to place a small metal tube called a stent inside the blocked section of bowel. The stent props the passage open like a tiny scaffold, buying time until the patient is strong enough for full surgery.
The other option is a diverting stoma (a surgically created opening in the abdomen that lets waste exit the body into a bag). The stoma bypasses the blockage while the tumor is treated and the patient is prepared for a bigger operation.
Both approaches are used worldwide. But which one leads to better long-term cancer outcomes? That question has not had a clear answer — until now.
The Stoma Takes Longer to Reach Surgery
Researchers in Sweden followed 56 patients treated for acute left-sided colorectal cancer blockages between 2003 and 2014. Half received a stent; the other group had a stoma placed. All patients eventually had their tumors removed with the goal of a cure.
One early difference stood out right away.
Patients in the stent group reached their full removal surgery in about 30 days on average. The stoma group waited nearly twice as long — about 55 days before the major operation.
After five years, 63 percent of stent patients were still alive, compared to 77 percent in the stoma group. That sounds like a meaningful difference. But here's the important detail: statistically, this gap was not significant (meaning it could easily be due to chance in a small group rather than a real difference between treatments).
Local recurrence — meaning the cancer coming back in the same spot — was equal. Two patients in each group experienced this.
Short-term complications, such as infections and bleeding after the initial procedure, were also similar between the two groups.
This does not mean the two approaches are identical — it means the study was too small to tell them apart with confidence.
The Perforation Risk No One Should Ignore
There is one risk that specifically applies to stents. When a metal stent is placed inside a tumor-narrowed bowel, there is a small chance the bowel wall can tear — a complication called perforation. In this study, one out of 24 stent patients (about 4 percent) experienced this.
Perforation is a serious event. It can allow cancer cells to spread into the abdomen, which could affect long-term survival. This is why some cancer surgeons are cautious about stents for patients whose tumors are in certain locations.
How It Fits Into the Bigger Picture
Doctors have been weighing stent versus stoma decisions for decades, and guidelines still vary by country and hospital. The stent approach is appealing because it is less invasive and may let patients skip a temporary stoma bag entirely. But the perforation concern keeps the debate alive.
This study adds to a growing body of evidence suggesting the two options may be roughly equivalent in terms of cancer outcomes. However, researchers are transparent that their data may simply not have included enough patients to detect a real difference — a problem statisticians call a "type II error."
If you or someone you care for is facing emergency colorectal cancer treatment, this is not a decision to make alone. The right choice depends on the tumor's location, the patient's overall health, and your surgical team's experience. Ask your doctor which option they recommend and why — and feel free to ask about the perforation risk associated with stents.
The Study's Limits Are Real
This was a single-center retrospective study (meaning researchers looked back at old records from one hospital). With only 56 patients spread across more than a decade, the numbers are too small to draw firm conclusions. Patient care also changed significantly over those 11 years, which may have affected results.
Larger, randomized controlled trials — where patients are randomly assigned to stent or stoma groups — are the next step needed to settle this question. Until those results arrive, both options remain on the table. Researchers and surgeons will continue refining their guidance as more data comes in.